Russell Investments Group Ltd. Takes Position in Proteostasis Therapeutics, Inc. (NASDAQ:PTI)

Russell Investments Group Ltd. acquired a new stake in Proteostasis Therapeutics, Inc. (NASDAQ:PTI) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,833 shares of the company’s stock, valued at approximately $100,000.

Separately, Teachers Advisors LLC boosted its position in Proteostasis Therapeutics by 21.4% in the fourth quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock valued at $155,000 after buying an additional 2,223 shares during the last quarter. 78.89% of the stock is owned by institutional investors and hedge funds.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) opened at 4.78 on Tuesday. The company’s market cap is $119.70 million. Proteostasis Therapeutics, Inc. has a 12 month low of $3.50 and a 12 month high of $20.63. The company has a 50 day moving average price of $4.15 and a 200-day moving average price of $9.40.

ILLEGAL ACTIVITY NOTICE: “Russell Investments Group Ltd. Takes Position in Proteostasis Therapeutics, Inc. (NASDAQ:PTI)” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/07/18/russell-investments-group-ltd-takes-position-in-proteostasis-therapeutics-inc-nasdaqpti.html.

Several research analysts have weighed in on the company. Zacks Investment Research cut Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, June 15th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Proteostasis Therapeutics in a research report on Friday, June 30th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $13.00 price objective on shares of Proteostasis Therapeutics in a research report on Sunday, April 2nd.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Want to see what other hedge funds are holding PTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Proteostasis Therapeutics, Inc. (NASDAQ:PTI).

Institutional Ownership by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

What are top analysts saying about Proteostasis Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteostasis Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit